NEW YORK – AstraZeneca has inked a deal with Jacobio Pharma for the exclusive rights to develop and commercialize the firm's pan-KRAS inhibitor outside of China. AstraZeneca is paying Jacobio $100 ...
NEW YORK – The convergence of gene-editing breakthroughs and new regulatory frameworks signaled a turning point in 2025 for getting gene therapies for rare diseases to patients. It's notoriously ...
Endometrial02, researchers want to see whether Enhertu can replace current standard-of-care chemotherapy for patients with HER2-expressing tumors.
NEW YORK – BioMarin has stopped developing the investigational BMN 349 for treating alpha-1 antitrypsin deficiency (AATD)-associated liver disease, the company announced in a regulatory filing this ...
RheumaGen will use the funds to advance its therapeutic development program in celiac disease through preclinical proof of concept.
The EGFR inhibitor's subcutaneous version heats up competition with AstraZeneca's Tagrisso in the front-line EGFR-mutated NSCLC space.
NEW YORK – Sangamo Therapeutics announced Thursday that it has initiated a rolling biologics license application (BLA) submission to the US Food and Drug Administration, seeking approval for its ...
NEW YORK – CAMP4 Therapeutics is supporting GSK's efforts to develop antisense oligonucleotide (ASO) drugs for neurodegenerative and kidney diseases. In a deal announced Thursday, CAMP4 said it will ...
NEW YORK – Nuvectis Pharma is starting a Phase Ib trial of its SRC and YES1 inhibitor NXP900 in combination with AstraZeneca's EGFR inhibitor Tagrisso (osimertinib) for patients with EGFR-mutated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback